Breaking News
Investing Pro 0
💎 Access the Market Tools Trusted by Thousands of Investors Get Started

Pakistan defers decision on drug price rise as pharma firms struggle

Published Mar 27, 2023 10:58AM ET Updated Mar 27, 2023 11:41AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
3/3 © Reuters. A customer buys medicine from a medical supply store in Karachi, Pakistan February 9, 2023. REUTERS/Akhtar Soomro 2/3
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

(Adds names of medicines in short supply, paragraph 11)

By Ariba Shahid and Asif Shahzad

KARACHI, Pakistan (Reuters) -Pakistan on Monday deferred a decision on a request by pharmaceutical firms to raise the prices of more than 100 medicines, prolonging a stand-off with an industry struggling to stem losses from soaring inflation and a weakened currency.

The request was discussed during a meeting of the finance ministry's Economic Coordination Committee, but no decision was taken, a ministry statement said. It was unclear when the matter would be discussed again, officials said.

Since June, local and multinational companies, including Sanofi (NASDAQ:SNY) SA, have been lobbying the government to raise prices through industry lobby groups the Pharma Bureau and the Pakistan Pharmaceutical Manufacturer's Association (PPMA).

Ayesha Tammy Haq, Executive Director of the Pharma Bureau, said some member companies have completely shut down, while others have cut output to offset production costs that have risen by 60% over the last six months. "We may hear of more shutdowns if things do not get better," she said.

Data from the statistics bureau compiled by Reuters showed the industry had cut overall output by 55% since June 2022. PPMA Chairman Farooq Bukhari said production could fall further. "If the government does not agree to adjust prices ..., the PPMA cannot keep telling pharma companies to continue production."

In addition to a global increase in the price of raw materials, the pharma companies have been hit by fiscal measures aimed at staving off economic collapse and securing more than $1 billion in funds from an International Monetary Fund bailout.

These measures include the removal of an artificial exchange rate for the rupee, which has fallen in value against the dollar by about a fifth since the start of the year. The country also suppressed imports, including inputs for the pharma sector earlier in the fiscal year as foreign exchange reserves dropped.

Inflation is also surging, hitting a 50-year-high of 31.5% in February, raising overall costs.

"The industry is asking for an across the board increase in prices on the basis of high inflation and unprecedented devaluation," a representative of Sanofi Aventis Pakistan Ltd said, declining to be named as company officials were not authorised to speak to the media.

Health Minister Abdul Qadir Patel recently met representatives of several pharma companies and discussed their demands, a spokesman told Reuters, without elaborating.

Higher drug prices will add to the pain of many Pakistanis already grappling with higher fuel and food prices. Due to the production cuts, the supply of some medicine for diabetes such as glimepiride and insulin, are running low, said Mustufa Bilwani, director of major pharmacy chain Dvago.

Pakistan defers decision on drug price rise as pharma firms struggle

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email